SCICLONE PHARMACEUTICALS INC Accounts Receivable, Credit Loss Expense (Reversal)
SCICLONE PHARMACEUTICALS INC reported Accounts Receivable, Credit Loss Expense (Reversal) of $541.00 thousand for the 12-month period ending 2015-12-31, per its 10-K filed 2017-03-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ProvisionForDoubtfulAccounts · last filed 2017-03-09
- SCICLONE PHARMACEUTICALS INC accounts receivable, credit loss expense (reversal) for the quarter ending 2015-12-31 was $0.00.
- SCICLONE PHARMACEUTICALS INC accounts receivable, credit loss expense (reversal) for the quarter ending 2015-09-30 was $0.00.
- SCICLONE PHARMACEUTICALS INC accounts receivable, credit loss expense (reversal) for the quarter ending 2015-06-30 was $0.00.
- SCICLONE PHARMACEUTICALS INC accounts receivable, credit loss expense (reversal) for the quarter ending 2015-03-31 was $541.00K.
- SCICLONE PHARMACEUTICALS INC accounts receivable, credit loss expense (reversal) for fiscal 2015 was $541.00K.
- SCICLONE PHARMACEUTICALS INC accounts receivable, credit loss expense (reversal) for fiscal 2013 was $2.54M.
| Period end | Accounts Receivable, Credit Loss Expense (Reversal) 3 month | Accounts Receivable, Credit Loss Expense (Reversal) 6 month | Accounts Receivable, Credit Loss Expense (Reversal) 9 month | Accounts Receivable, Credit Loss Expense (Reversal) 12 month |
|---|---|---|---|---|
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-09 | $0.00 derived: sum of 2 quarters · filed 2017-03-09 | $0.00 derived: sum of 3 quarters · filed 2017-03-09 | $541.00K 10-K · filed 2017-03-09 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $0.00 derived: sum of 2 quarters · filed 2016-11-09 | $541.00K 10-Q · filed 2016-11-09 | |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $541.00K 10-Q · filed 2016-08-09 | ||
| 2015-03-31 | $541.00K 10-Q · filed 2016-05-10 | |||
| 2013-12-31 | $1.49M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-11 | $2.54M 10-K · filed 2016-03-11 | ||
| 2013-09-30 | $1.05M 10-Q · filed 2014-11-10 |